Volume 28, Issue 150, August 2024

Trends in weight change pattern among adults with type 2 diabetes mellitus using dapagliflozin 10mg and Semaglutide 1mg in King Abdulaziz Medical City, Riyadh, Saudi Arabia

Eman Alharbi^1♦, Khalid Alharbi², Mohammed AlSahly²

¹Diabetes Clinical Fellow at University Diabetes Center, King Saud University Medical City, Riyadh, Kingdom of Saudi Arabia
²Resident at Family Medicine Department, King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia

^♦Corresponding Author
Diabetes clinical fellow at University Diabetes Center, King Saud University Medical City, Riyadh, Kingdom of Saudi Arabia

ABSTRACT

Diabetes is a common disease characterized by impaired glycemic control in the body. We used a retrospective, chart review study design to collect the A1c readings in patients using Dapagliflozin 10mg. The total sample size was 107 participants. 57 participants were on Dapagliflozin, 33 on Semaglutide, and 17 were on a combination of Semaglutide and Dapagliflozin. Weight significantly decreased in participants using Dapagliflozin and Semaglutide combination (p<0.001) compared to those using Semaglutide alone (p<0.001). Additionally, HbA1c significantly decreased among participants using Dapagliflozin and Semaglutide (p<0.001) and those using Dapagliflozin alone (p<0.001). Even though SGLT-2 inhibitors weakly reduce HbA1c, we have found in our study that Dapagliflozin has significantly decreased A1c in addition to a reduction in weight especially among females.

Keywords: Type 2 diabetes mellitus, hba1c, semaglutide, dapagliflozin, sglt-2 inhibitors

Medical Science, 2024, 28, e107ms3405

PDF

DOI: https://doi.org/10.54905/disssi.v28i150.e107ms3405

Published: 21 August 2024